ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and

2024年3月22日，艾伯维（AbbVie）宣布，美国FDA已完全批准其“first-in-class”抗体偶联药物（ADC）Elahere（mirvetuximab soravtansine）用于治疗 叶酸受体α （FRα）阳性、 铂类耐药 的 上皮性卵巢癌 、 输卵管癌 或 原发性腹膜癌 患者，这些患者既往接受过至多3种全身治疗 ...

ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant...

Elahere (mirvetuximab soravtansine-gynx) is an injectable antibody-drug conjugate that may be used to treat adults with folate receptor-alpha (FRα) -positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have alr

Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [2] [5] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. [5] [6]

On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive,...

Elahere is a cancer medicine used for the treatment of adult patients with advanced cancers of the ovaries fallopian tubes (the tubes connecting ovaries to the uterus) and the peritoneum (the membrane lining the abdomen).

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

2024年10月24日 · ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have ...

2025年3月16日 · AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE ® (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements ...